Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.
Abstract
The detailed examination of the antibody repertoire from RV144 provides a unique template
for understanding potentially protective antibody functions. Some potential immune
correlates of protection were untested in the correlates analyses due to inherent
assay limitations, as well as the need to keep the correlates analysis focused on
a limited number of endpoints to achieve statistical power. In an RV144 pilot study,
we determined that RV144 vaccination elicited antibodies that could bind infectious
virions (including the vaccine strains HIV-1 CM244 and HIV-1 MN and an HIV-1 strain
expressing transmitted/founder Env, B.WITO.c). Among vaccinees with the highest IgG
binding antibody profile, the majority (78%) captured the infectious vaccine strain
virus (CM244), while a smaller proportion of vaccinees (26%) captured HIV-1 transmitted/founder
Env virus. We demonstrated that vaccine-elicited HIV-1 gp120 antibodies of multiple
specificities (V3, V2, conformational C1, and gp120 conformational) mediated capture
of infectious virions. Although capture of infectious HIV-1 correlated with other
humoral immune responses, the extent of variation between these humoral responses
and virion capture indicates that virion capture antibodies occupy unique immunological
space.
Type
Journal articleSubject
AIDS VaccinesAntibodies, Neutralizing
Antibodies, Viral
Antibody Specificity
HIV Envelope Protein gp120
HIV-1
Humans
Immunoglobulin G
Pilot Projects
Viral Vaccines
Virion
Permalink
https://hdl.handle.net/10161/14726Published Version (Please cite this version)
10.1128/JVI.02737-12Publication Info
(2013). Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol, 87(14). pp. 7828-7836. 10.1128/JVI.02737-12. Retrieved from https://hdl.handle.net/10161/14726.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
S. Munir Alam
Professor in Medicine
Research Interests.
The Alam laboratory’s primary research is focused on understanding the biophysical
properties of antigen-antibody binding and the molecular events of early B cell activation
using the HIV-1 broadly neutralizing antibody (bnAb) lineage models. We are studying
how HIV-1 Envelope proteins of varying affinities are sensed by B cells expressing
HIV-1 bnAbs or their germline antigen receptors and initiate early signaling events
for their activation. In the lon
Mattia Bonsignori
Associate Professor in Medicine
HIV vaccine development Study of B-cell immune responses in HIV positive individuals
Determination of correlates of protective immunity to HIV Induction of broadly neutralizing
antibodies to HIV Development of multiplex functional assays for the evaluation at
a single-cell level of B-cell responses to vaccinations, infections and in vitro stimulation
Epidemiology and characterization of bacterial resistance determinants (past) </do
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
Thomas Norton Denny
Professor in Medicine
Thomas N. Denny, MSc, M.Phil, is the Chief Operating Officer of the Duke Human Vaccine
Institute (DHVI), Associate Dean for Duke Research and Discovery @RTP, and a Professor
of Medicine in the Department of Medicine at Duke University Medical Center. He is
also an Affiliate Member of the Duke Global Health Institute. Previously, he served
on the Health Sector Advisory Council of the Duke University Fuquay School of Business.
Prior to joining Duke, he was an Associate Professor of Pathology, Labo
Guido Ferrari
Professor in Surgery
The activities of the Ferrari Laboratory are based on both independent basic research
and immune monitoring studies. The research revolves around three main areas of interest:
class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity
(ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With
continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation
along with many other productive collaborations wi
Barton Ford Haynes
Frederic M. Hanes Distinguished Professor of Medicine
Barton F. Haynes, M.D. is the Frederic M. Hanes Professor of Medicine and Immunology,
and Director of the Duke Human Vaccine Institute. Prior to leading the DHVI, Dr. Haynes
served as Chief of the Division of Rheumatology, Allergy and Clinical Immunology,
and later as Chair of the Department of Medicine. As Director of the Duke Human Vaccine
Institute, Bart Haynes is leading a team of investigators working on vaccines for
emerging infections, including tuberculosis, pandemic influenza, emergi
Hua-Xin Liao
Adjunct Professor in the Department of Medicine
Dr. Liao is a Professor of Medicine and Research Director of Duke Human Vaccine Institute.
Dr. Liao is a MD virologistt rained in China. In early 1980’s, Dr. Liao made
major contributions to the first isolation of epidemic hemorrhagic fever virus (hataanvirus)
from Apodemus agraius using tissue culture in China. The successful identification
and isolation of Hataanvirus enabled the early diagnosis and treatment of the disease,
and advancement of HFRS research towards prevention by de
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
David Charles Montefiori
Professor in Surgery
Dr. Montefiori is Professor and Director of the Laboratory for HIV and COVID-19 Vaccine
Research & Development in the Department of Surgery, Division of Surgical Sciences
at Duke University Medical Center. His major research interests are viral immunology
and HIV and COVID-19 vaccine development, with a special emphasis on neutralizing
antibodies. Multiple aspects of HIV-1 neutralizing antibodies are studied in his laboratory,
including mechanisms of neutralization and escape,
Michael Anthony Moody
Professor of Pediatrics
Tony Moody, MD is a Professor in the Department of Pediatrics, Division of Infectious
Diseases and Professor in the Department of Integrative Immunobiology at Duke University
Medical Center. Research in the Moody lab is focused on understanding the B cell responses
during infection, vaccination, and disease. The lab has become a resource for human
phenotyping, flow characterization, staining and analysis at the Duke Human Vaccine
Institute (DHVI). The Moody lab is currently funded to study in
Xiaoying Shen
Associate Professor in Surgery
Dr. Shen is an Associate Director and Deputy of the Laboratory for HIV and COVID-19
Vaccine Research & Development in the Department of Surgery, Division of Surgical
Sciences at Duke University Medical Center. Her research interest focuses on the humoral
immune response following virus infection or vaccination. During the past decade,
she has worked intensively on the specificity and breadth of binding antibody responses
against HIV. Dr. Shen’s team developed assays and
Georgia Doris Tomaras
Professor in Surgery
Dr. Georgia Tomaras is a tenured Professor of Surgery, Professor of Immunology, Professor
of Molecular Genetics and Microbiology and is a Fellow of the American Academy of
Microbiology (AAM) and a Fellow of the American Association for the Advancement of
Science (AAAS). Dr. Tomaras is Co-Director of the Center for Human Systems Immunology
(CHSI) Duke University and Director of the Duke Center for AIDS Research (CFAR). Her
national and international leadership roles i
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info